OncoZenge reports nine-month BupiZenge stability within specs
OncoZenge says nine-month stability data for BupiZenge are within specifications at 25°C/60% RH, 40°C/75% RH, and 30°C/75% RH, supporting supply for its Phase III BEAM-Pain trial and partner discussions.